Time filter

Source Type

Cambridge, MA, United States

Hendriks B.S.,Merrimack Pharmaceutical Inc.
Current Opinion in Chemical Biology | Year: 2010

Decades of signal transduction research have elucidated a complex and dynamic architecture of signaling pathways and networks that are associated with cellular responses, physiological responses as well as various pathologies. Consequently, there is great interest in pharmacological manipulation of these pathways for therapeutic purposes. Pathway complexity brings forth two distinct challenges, one in the systematic generation of pathway-level datasets under multiple conditions and one in the interpretation of such complex data. Mechanistic model-based analysis has been used to aid in drug discovery and development, specifically in understanding and predicting the interaction of small molecule inhibitors with pathways. Examples including the quantitative comparison of multiple compounds and mechanisms of action, target selection and the elucidation of clinical findings are reviewed. © 2010 Elsevier Ltd.

Merrimack Pharmaceutical Inc. | Date: 2015-12-28

The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.

Merrimack Pharmaceutical Inc. | Date: 2015-06-11

Described are methods of selecting appropriate therapy for, or optimizing therapeutic efficacy of treatment of, a patient having a cancer using biomarker readings obtained from a biological sample of the cancer from the patient and, based on the readings obtained, treating the patient with MM-111 in combination with trastuzumab and one of the following: a receptor tyrosine kinase inhibitor, a mitogen-activated protein kinase kinase (MEK) inhibitor, and a protein kinase B (AKT) inhibitor.

Methods for treating cancer patients (e.g., cancer patients resistant or intolerant to pertuzumab and ado-trastuzumab emtansine) having HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of a doxorubicin-loaded immunoliposome with a targeting moiety that is an anti-HER2 antibody that is not an inhibitor of HER2 signaling and an anti-cancer therapeutic comprising a doxorubicin-free anti-cancer therapeutic comprising a different anti-HER2 antibody.

Provided are methods for optimizing therapy of, treating a patient having, or selecting (identifying) patients who will benefit from treatment for, a cancer (e.g., a non-hematological cancer; e.g., a gynecological cancer). The methods comprise determining whether the patient will benefit from treatment with an ErbB3 inhibitor (e.g., an anti-ErbB3 antibody), with or without either a taxane or an aromatase inhibitor, or with a taxane or an aromatase inhibitor in the absence of an ErbB3 inhibitor, based on levels of particular biomarkers and combinations of biomarkers measured in a biological sample obtained from the patient. The methods further comprise optimizing the patients therapy, selecting the patient for treatment, or treating the patient accordingly. In various aspects the biological samples are sections of a biopsy (e.g., a formalin fixed paraffin embedded biopsy). In other aspects the biomarkers are proteins and/or nucleic acids. In other aspects the biomarkers function in ErbB-mediated signal transduction.

Discover hidden collaborations